| Drug Name |
Vedolizumab |
| Drug ID |
BADD_D02342 |
| Description |
Vedolizumab is a recombinant humanized IgG1 monoclonal antibody directed against the human lymphocyte α4β7 integrin, a key mediator of gastrointestinal inflammation. It is used in the treatment of moderate to severe active ulcerative colitis and Crohn's disease for patients who have had an inadequate response with, lost response to, or were intolerant to inhibitors of tumor necrosis factor-alpha (TNF-alpha) or other conventional therapies. By blocking its primary target, α4β7 integrin, vedolizumab reduces inflammation in the gut. Vedolizumab is administered by IV infusion over a period of 30 minutes; after the first dose, it is given again at two and six weeks and then every 8 weeks thereafter. |
| Indications and Usage |
Vedolizumab is indicated for adult patients with moderately to severely active UC or CD who have had an inadequate response with, lost response to, or were intolerant to a tumor necrosis factor (TNF) blocker or immunomodulator; or had an inadequate response with, were intolerant to, or demonstrated dependence on corticosteroids. |
| Marketing Status |
approved |
| ATC Code |
L04AA33 |
| DrugBank ID |
DB09033
|
| KEGG ID |
D08083
|
| MeSH ID |
C543529
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
D0PK5M
|
| NDC Product Code |
64764-300; 0051-2638; 11532-3002 |
| UNII |
9RV78Q2002
|
| Synonyms |
vedolizumab | Entyvio | MLN0002 | MLN02 | MLN-0002 | MLN-02 |
